The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) International Journal of Molecular Sciences Année : 2023

The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics

Résumé

Cisplatin (cis-diamminedichloroplatinum I) is a platinum-based drug, the mainstay of anticancer treatment for numerous solid tumors. Since its approval by the FDA in 1978, the drug has continued to be used for the treatment of half of epithelial cancers. However, resistance to cisplatin represents a major obstacle during anticancer therapy. Here, we review recent findings on how the mTORC1 pathway and autophagy can influence cisplatin sensitivity and resistance and how these data can be applicable for the development of new therapeutic strategies.
Fichier principal
Vignette du fichier
Pan IJMS 2023.pdf (2.39 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04300997 , version 1 (22-11-2023)

Identifiants

Citer

Zhenrui Pan, Hanxiao Zhang, Svetlana Dokudovskaya. The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics. International Journal of Molecular Sciences, 2023, 24 (13), pp.10651. ⟨10.3390/ijms241310651⟩. ⟨hal-04300997⟩
16 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More